Trial Profile
Phase II Study of RAD001 monotherapy in Patients With Unresectable Pheochromocytoma or Extra-adrenal Paraganglioma or Non-functioning Carcinoid
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Carcinoid tumour; Neuroendocrine tumours; Paraganglioma; Phaeochromocytoma
- Focus Therapeutic Use
- Acronyms PheoCarcRAD001
- 19 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Jul 2010 New trial record